MRI Scan Liver Fat Quantification, in Visit Clinic

Yes. MRI techniques such as proton density fat fraction (PDFF) and MR spectroscopy can noninvasively and quantitatively measure liver fat with high accuracy and reproducibility. They detect and monitor hepatic steatosis across a wide range of fat content, correlate well with biopsy, and help track treatment. Limitations include cost, availability, confounding by iron or severe fibrosis, and limited assessment of inflammation.

Quantifying liver fat is done by: MRI-PDFF (most accurate noninvasive measure) or MR spectroscopy for precise fat fraction; controlled attenuation parameter (CAP) on FibroScan for point-of-care quantification; CT attenuation and ultrasound (mainly qualitative); and liver biopsy (definitive but invasive). Blood-based indices (e.g., Fatty Liver Index) screen risk but don’t measure fat directly. Choice depends on accuracy, availability, cost and invasiveness.

Fat fraction on MRI is calculated as the proton density fat fraction (PDFF): PDFF(%) = 100 × S_fat / (S_fat + S_water). Practically, acquire multi‑echo chemical‑shift (Dixon/IDEAL) images, perform complex water–fat separation with T2* and spectral modeling corrections, generate voxelwise fat and water maps, then compute PDFF per voxel and average over the region of interest, accounting for T1, noise and other confounders.

MRI can quantify and map body fat accurately, distinguishing subcutaneous and visceral adipose tissue and allowing precise regional or whole‑body fat calculations when images are segmented. It’s mainly used in research and some clinical settings because scans are expensive, time‑consuming and require specialized analysis. For routine body‑fat percentage estimates clinicians more often use DEXA, bioelectrical impedance or skinfold methods.

For fatty liver, MRI-PDFF is the most accurate noninvasive scan for quantifying liver fat. Transient elastography (FibroScan) with controlled attenuation parameter offers excellent point-of-care assessment and simultaneously evaluates fibrosis and steatosis. Ultrasound is widely used for initial screening but is less sensitive for mild steatosis; CT is rarely used due to radiation.

Yes—severe (grade 3) fatty liver can often be substantially improved or reversed if caught before advanced fibrosis or cirrhosis. Significant, sustained lifestyle changes (weight loss of 7–10% or more, healthy diet, regular aerobic and resistance exercise), strict alcohol avoidance, and control of diabetes, lipids and blood pressure are key. Advanced scarring may be only partially reversible; medical follow-up is essential.